MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (?)
Ratings Breakdown: 2 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $10.20 (26.55% upside)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Show:
DateFirmActionRatingPrice TargetActions
6/12/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Robert W. BairdReiterated RatingOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Jefferies GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Maxim GroupReiterated RatingBuy$11.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2015William BlairReiterated RatingOutperform$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015JMP SecuritiesDowngradeOutperform -> Market Perform$24.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2015Deutsche BankReiterated RatingBuy$25.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2015BarclaysInitiated CoverageUnderweight$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/12/2014Wells FargoReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/21/2014Credit SuisseReiterated RatingNeutral$4.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/15/2014FBR & Co.Initiated CoverageOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2014Piper JaffrayUpgradeNeutral -> Overweight$5.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4$0.09$0.12$31.40 million$31.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q414($0.18)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.16)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20163($0.16)($0.16)($0.16)
Q3 20161($0.19)($0.19)($0.19)
Q4 20163($0.23)($0.17)($0.19)
(Data provided by Zacks Investment Research)
Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateHeadline
06/27/16 07:03 AMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Broker Price Targets For The Coming Week - Fiscal Standard
06/26/16 02:16 PMStock Performance Focus on: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Press Telegraph
06/22/16 07:04 AMFirst Week of August 19th Options Trading For Achillion Pharmaceuticals (ACHN)
06/21/16 10:20 AMAchillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : June 21, 2016 -
06/21/16 07:04 AMWorth Watching Stock: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - iStreetWire
06/20/16 05:51 PMWhy Achillion Pharmaceuticals Is Down Big in 2016 - Progress on short-duration hepatitis C therapies has failed to ignite investors' interest.
06/20/16 02:17 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/20/16 07:25 AMAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : June 20, 2016 -
06/17/16 10:12 AMYesterday Stock's Price Swings: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , Spark Therapeutics, Inc. (NASDAQ ... - Street Updates
06/16/16 02:18 PMAnalyst Recommended Stock: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - News Oracle
06/16/16 02:18 PMPrice Target Summary: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Smith & Wesson Holding Corporation ... - Beacon Chronicle
06/14/16 02:17 PMEarnings Expectations of the Stocks: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Tesoro Corporation (NYSE:TSO) - Beacon Chronicle
06/14/16 02:17 PMEarnings Expectations of the Stocks: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Tesoro Corporation (NYSE:TSO) - Beacon Chronicle
06/14/16 07:04 AMEarnings Expectation Watch List: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), HD Supply Holdings, Inc ... - Beacon Chronicle
06/13/16 02:17 PMHC Stocks News Ring: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), OXiGENE Inc (NASDAQ:OXGN) - share market updates (press release)
06/11/16 07:45 PMHot Stock under Consideration: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - News Oracle
06/10/16 10:40 AMAnalyst Opinion on these Stocks: Investors Bancorp Inc. (NASDAQ:ISBC), Achillion Pharmaceuticals, Inc. (NASDAQ ... - Beacon Chronicle
06/10/16 02:30 AMAchillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association - [GlobeNewswire] - -Results indicate up to 100% inhibition of alternative-pathway activity in hemolysis and Wieslab assays after oral dosing of ACH-4471-. -Results support initiation of phase 1 multiple-ascending trial during ...
06/09/16 02:15 PMAnalyst Overview on these Stocks: UBS Group AG (NYSE:UBS), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Beacon Chronicle
06/07/16 07:52 PMPrice Target Summary Report: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Adobe Systems Incorporated ... - Beacon Chronicle
06/06/16 02:18 PMPrice Target Summary: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), DeVry Education Group Inc. (NYSE:DV) - Beacon Chronicle
06/05/16 10:09 AMAchillion Pharmaceuticals, Inc. (ACHN) Given “Market Perform” Rating at Leerink Swann - Let Me Know About This
06/03/16 08:16 PMBuy Sell or Hold? - Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), General Mills, Inc. (NYSE:GIS) - Beacon Chronicle
06/02/16 08:14 PMBaird's Focus Ideas: Gilead Sciences, Inc. (GILD), Achillion Pharmaceuticals, Inc. (ACHN) - Smarter Analyst - Baird's Focus Ideas: Gilead Sciences, Inc. (GILD), Achillion Pharmaceuticals, Inc. (ACHN)Smarter AnalystWith summer approaching, most of the major brokerage firms are making some changes and additions to their firms top stock ideas. At one of the top regional brokerage firms, Baird, they are making some additions to the firm's Focus Idea list that look ...and more »
06/02/16 04:21 PMWhy Achillion Pharmaceuticals Jumped 10% in May - The potential for its clinical stage drugs to significantly shorten the duration of hepatitis C treatment could prove profit-friendly.
06/02/16 10:55 AMPrice Target by Analysts: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Rovi Corporation (NASDAQ:ROVI) - Beacon Chronicle - Beacon ChroniclePrice Target by Analysts: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Rovi Corporation (NASDAQ:ROVI)Beacon ChronicleLast Trade: The Company closed its last session at $9.42 with the gain of 0.75%. The market capitalization of the company is $1.28 Billion, with the average Volume of 1.45 Million. The stock currently has its 52-Week High range of $10.95 and 52-week ...and more »
06/01/16 08:20 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). The latest reports which are currently in issue on Wednesday 1st of June state 0 analysts have a rating of “strong buy”, ...and more »
06/01/16 03:25 PMAchillion to Present at Three Upcoming Investor Conferences - [at noodls] - NEW HAVEN, Conn., June 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will ...
05/27/16 03:49 PMHealthcare Stocks to Track: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Achillion Pharmaceuticals, Inc.(NASDAQ ... - NYSE Journal (press release) - Healthcare Stocks to Track: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Achillion Pharmaceuticals, Inc.(NASDAQ ...NYSE Journal (press release)Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN), remained flat and closed at $9.05 in the last trading session. The last trading range of the stock ranges between $8.87 and $9.15. The company's Market capitalization is $1.26 Billion with the total ...and more »
05/27/16 03:49 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) at $9.05: How much higher it can go - iStreetWire - iStreetWireAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) at $9.05: How much higher it can goiStreetWireAchillion Pharmaceuticals, Inc. (ACHN) up 10.91 per cent in the past week, is under coverage of 7 analysts who collectively recommend a hold rating on stock. 3 of the analysts have a buy or better rating; the 0 sells versus 1 underperforms. The 5 ...Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Analysts Quick Take on EarningsNews TribuneEPS Growth Check Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)The PostActive Stock Rundown: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)Wall Street Hints and Newsall 4 news articles »
05/27/16 03:06 PMACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi -
05/26/16 08:47 PMWhat Analyst Recommend Regarding Stocks? Boston Scientific Corporation (NYSE:BSX), Achillion Pharmaceuticals - (NYSE:STJ) after beginning at $77.04, closed at $77.44 by building up +0.56% in recent trading session. Achillion Pharmaceuticals, Inc.'s (ACHN) has price-to-cash ratio of 2.72 and price to sale ratio of 18.11. The stock price is moving up from its 20 days ...
05/22/16 08:19 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) To Present Abstract At European Hematology Association - Market Exclusive - News OracleAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) To Present Abstract At European Hematology AssociationMarket ExclusiveAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has announced that it will be presenting a late-breaking abstract summarizing ACH-4471 during the Congress of European Hematology Association. The e-poster will be based on the fact that ACH-4471, ...Biotech Companies To Look Out For: Mast Therapeutics, Inc. (MSTX), Achillion Pharmaceuticals, Inc. (ACHN)ZergwatchAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Earns Consensus Hold RatingStreet RegisterAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , Bruker Corporation (NASDAQ:BRKR): Yesterday Trading RecapStreet UpdatesRisers & Fallers -Share Trading News -News Oracleall 19 news articles »
05/20/16 03:30 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) To Present Abstract At European Hematology Association - Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has announced that it will be presenting a late-breaking abstract summarizing ACH-4471 during the Congress of European Hematology Association. The e-poster will be based on the fact that ACH-4471, a ...
05/19/16 05:05 AMAchillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association - [GlobeNewswire] - -Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers-. NEW HAVEN, Conn., May 19, ...
05/14/16 02:03 AMDoheny Asset Management /ca Sells A Lot More Achillion Pharmaceuticals, Inc. (ACHN) Stock - Finance Daily - Doheny Asset Management /ca Sells A Lot More Achillion Pharmaceuticals, Inc. (ACHN) StockFinance DailyDoheny Asset Management /ca sold 348,900 shares in the previous quarter decreasing its holdings in Achillion Pharmaceuticals, Inc. by 75.8%. Its investment was valued at $862,000 a decrease of $4,107,000 according to the filing. The following firms ...Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Updated Broker RatingsRisers & FallersAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Stock Target from AnalystsNews Tribuneall 6 news articles »
05/13/16 08:55 PMDoheny Asset Management /ca Sells A Lot More Achillion Pharmaceuticals, Inc. (ACHN) Stock - Doheny Asset Management /ca sold 348,900 shares in the previous quarter decreasing its holdings in Achillion Pharmaceuticals, Inc. by 75.8%. Its investment was valued at $862,000 a decrease of $4,107,000 according to the filing. The following firms have ...
05/12/16 03:50 PMComplete Analysis of: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - News Oracle - Complete Analysis of: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)News OracleLast Trade: The Company rose 0.59% and finished at $8.31. The daily volume was measured at 1.01 million shares. The 52-week high of the share price is $11.05 and the 52-week low is $5.57. The company has a market cap of $1.14 billion. Its latest ...and more »
05/11/16 05:21 PMETF’s with exposure to Achillion Pharmaceuticals, Inc. : May 11, 2016 -
05/10/16 12:04 PMACHILLION PHARMACEUTICALS INC Financials -
05/10/16 07:05 AMAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : May 10, 2016 -
05/08/16 03:48 PMAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Broker Price Targets For The Coming Week - Share Trading News - Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/05/16 03:57 PMTrading the Biotech News: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Gilead Sciences Inc. (NASDAQ:GILD) - Street Register - Trading the Biotech News: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Gilead Sciences Inc. (NASDAQ:GILD)Street RegisterAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) lost -2.79% by the end of recent close at $8.02. For the ongoing quarter, the 7 Wall Street analysts providing adjusted earnings per share outlook have a consensus estimate of $-$0.15/share, which would ...and more »
05/03/16 08:52 PMAchillion Pharmaceuticals Inc. (ACHN) Drops 6.46% on May 03 - Equities.com - Achillion Pharmaceuticals Inc. (ACHN) Drops 6.46% on May 03Equities.comAchillion Pharmaceuticals Inc. (ACHN) was one of the Russell 2000's biggest losers for Tuesday May 03 as the stock slid 6.46% to $8.25, a loss of $-0.57 per share. Starting at an opening price of $8.65 a share, the stock traded between $8.12 and $8.76 ...and more »
05/03/16 03:20 PMACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/03/16 03:17 PMACHILLION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
05/03/16 05:30 AMAchillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs - [at noodls] - - Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 - - Strong balance ...
05/03/16 05:28 AM6:28 am Achillion Pharma beats by $0.01 -
05/03/16 05:19 AMAchillion reports 1Q loss -
05/03/16 05:12 AMAchillion Pharmaceuticals beats by $0.01 -
About Achillion Pharmaceuticals

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ACHN
  • CUSIP: 00448Q20
Key Metrics:
  • Previous Close: $8.71
  • 50 Day Moving Average: $8.79
  • 200 Day Moving Average: $8.21
  • P/E Ratio: N/A
  • P/E Growth: -0.76
  • Market Cap: $1.10B
  • Current Quarter EPS Consensus Estimate: $-0.65 EPS
Additional Links:
Achillion Pharmaceuticals (NASDAQ:ACHN) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha